A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma

This phase I, open-label, uncontrolled, ascending-dose study explored the safety, maximum tolerated dose (MTD), pharmacokinetics, and pharmacology of the TLR8 agonist VTX-2337 in subjects with advanced solid tumors or lymphoma. VTX-2337 doses (0.1-3.9 mg/m(2)) were administered subcutaneously on day...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2014-07, Vol.20 (14), p.3683-3691
Hauptverfasser:	Northfelt, Donald W, Ramanathan, Ramesh K, Cohen, Peter A, Von Hoff, Daniel D, Weiss, Glen J, Dietsch, Gregory N, Manjarrez, Kristi L, Randall, Tressa D, Hershberg, Robert M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Antineoplastic Agents - toxicity Benzazepines - pharmacokinetics Benzazepines - therapeutic use Benzazepines - toxicity Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Female Humans Injections, Subcutaneous Lymphoma - drug therapy Lymphoma - pathology Male Maximum Tolerated Dose Middle Aged Neoplasm Staging Toll-Like Receptor 8 - agonists Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!